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Blood Vessel Formation: Minireview
What Is Its Molecular Basis?
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Boston, Massachusetts 02115 their contribution to vascular development.
Three papers in this issue reveal new information
Medical students learning the anatomy of the human about the potential role of the TIE2 receptor and its
ligand and raise interesting questions about the detailscardiovascular system recognize that the blood vessels
are named mainly on the basis of luminal diameter, of vessel assembly. The paper by Davis et al. (1996, this
issue) reports the isolation and cloning of angiopoietin-1branching, position, and organ supplied. Students and
physicians rely upon the general constancy of vascular (a 70 kD glycoprotein), the first known ligand of the TIE2
receptor which is expressed on vascular endothelialdeterminants from one individual to another and take
for granted that anatomy books will not go out of date. cells. Interestingly, unlike VEGF, angiopoietin-1 is nei-
ther a mitogen for endothelium, nor does it induce tubeIt is only when they learn that these vessels with their
proper diameters and branches are formed in the em- formation in vitro. Rather, its pattern of expression in
the vicinity of forming vessels suggests that it plays abryo, mostly before the heart starts beating, that stu-
dents begin to appreciate the true complexity of the role in regulating the assembly of non-endothelial vessel
wall components. This supposition is supported by ob-genetic program that governs the development of the
vascular system. This appreciationdeepens when errors servations in the paper by Suri et al. (1996, this issue) in
which mice deficient for angiopoietin-1 exhibit abnormalof the basic developmental plan are revealed as ‘vascu-
lar malformations.’ vascular architecture where the principal defect is a
failure to recruitsmooth muscle and pericyte precursors.The genetic and molecular mechanisms that control
the development of the vascular system have remained In the heart, this defect manifests as poorly developed
endocardium, characterized by incomplete associationa mystery, until recently. Driven in part by the study of
tumor angiogenesis in the 1970s, increased understand- of the endothelial layer with the underlying myocardial
wall.ing of the growth of capillary blood vessels led to long-
term in vitro culture of capillary endothelial cells and to In the paper by Vikkula et al. (1996, this issue), venous
malformations in two disparate families were mappeddiscovery of proteins that are mitogenic for these cells,
including basic fibroblast growth factor (bFGF) and vas- to the Tie2 receptor where a missense mutation results
in an arginine-to-tryptophan substitution. By overex-cular endothelial growth factor (VEGF), among others.
The role of these proteins in vascular development is pressing the full-length and wild-type mutant receptors
in insect cells, theauthors show that themutant receptorcurrently the subject of active investigation.
Generation of angioblasts from mesoderm appears to has a 6 to 10-fold increase in autophosphorylation activ-
ity. Patients carrying this mutation develop vein-likerequire the action of members of the fibroblast growth
factor family (References can be found in Flamme and structures that are deficient in the non-endothelial cells
of the vascular wall, mainlya lack of smooth muscle cellsRisau, 1992). The mesoderm-derived angioblasts then
differentiate into endothelial cells which form de novo (Figure 1). Thus, these malformations are comprised of
vein-like lumens lined by a monolayer of endothelialvessels including the dorsal aorta. VEGF seems to be
essential to this process of vasculogenesis, the earliest cells, but with thin walls in which smooth muscle layers
are markedly reduced, as compared to normal vesselsformation of blood vessels in the embryo. Two receptors
for VEGF are expressed by angioblasts and by the endo- with similar sized lumens. As the luminal diameter of
normal veins increases, there is a proportional increasethelial cells, which arise from them. Disruption of the
gene for the receptor VEGFR-2 (flk-1), interferes with in the number of smooth muscle cell layers (Saenz et al.,
1991). In contrast, venous malformations exhibit widethe differentiation of endothelial cells, leading to death
of embryos at day 8.5-9.5 (Shalaby et al., 1995). Disrup- variations in luminal size (including diameters larger than
any normal vessels), but without a complementary in-tion of the gene for the other receptor VEGFR-1 (flt-1)
permits differentiation of endothelial cells, but interferes crease in smooth muscle layers with increasing vessel
diameter.with a later stage of vasculogenesis, resulting in thin-
walled vessels of larger than normal diameter and the These reports are exciting because a vascular abnor-
mality in both mice and humans is defined by a receptor-embryo’s death at day 9 (Fong et al., 1995). Mice made
deficient for VEGF by targeted disruption of the gene ligand system on the vascular endothelial cell. It is intri-
guing that an apparent defect in vascular remodelingdie at 8.5-9 days gestation with delayed differentiation of
endothelial cells and impairment of bothvasculogenesis can result either from an activating mutation of the re-
ceptor (Vikkula et al., 1996), from the absence of theand angiogenesis (sprouting of new capillary vessels
from pre-existing vasculature) (Carmeliet et al., 1996a; ligand (Suri et al., 1996), or from a deficiency of the TIE2
receptor itself (previously reported by Sato et al., 1995).Ferrara et al., 1996).
The cloning of TIE1 and TIE2 (also called Tek) tyrosine However, while each situation reveals a general abnor-
mality in vascular remodeling, there may be subtle butkinases added another chapter to this story (Dumont et
al., 1992). The phenotype of mice deficient for these important differences.
The human activating mutation of the TIE2 receptorreceptors indicates that they play a role in angiogenesis
and remodeling that issubsequent to theaction of VEGF, and the murine ligand (angiopoietin-1) deficiency both
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as simple as a vein, appears to involve several different
molecular pathways. When the papers in this issue of
Cell on TIE2/angiopoietin are considered together with
previous reports of vascular phenotypes resulting from
targeted disruption of other genes involved in vascular
development, a working model of vessel assembly can
be constructed.Fifty percent of TGF-b null mice die from
a severe defect in yolk-sac vasculogenesis, thought to
result from improper interactions between epithelial and
mesenchymal cells (Dickson et al., 1995). Platelet-
derived growth factor receptor-b (PDGFR-b) and
PDGF-B ligand-null mice die perinatally from hemor-
rhage and have no pericytes (mesangial cells) in the
kidney vasculature (Leve´en et al., 1994; Soriano, 1994).
Furthermore, these animals are reported to lack peri-
cytes throughout the entire microvascular bed (C. Betz-
holz, submitted). In addition, a recent study reports that
mice deficient for tissue factor, die in utero at day 8.5
with vascular abnormalities that appear to be due to a
defect in recruitment of smooth muscle/pericytes (Car-
meliet et al., 1996b). (Because of our relative lack of
knowledge about the actions of tissue factor outside of
its function in coagulation, it is difficult to speculate what
precise role tissue factor might play in vessel assembly.)
The paper by Suri et al. concludes that the absence
of angiopoietin-1 results in vessels that “do not properly
recruit supporting cells” to the vascular wall. The Vikkula
paper also speculates that the activating mutation of
the TIE2 receptor is somehow linked to a deficient re-
cruitment of mesenchymal cells to the vascular wall.
They proposethat TIE2receptor expression by endothe-
lial cells regulates ligand expression by smooth muscle
cells so that the activating mutation in TIE2 would lead
to decreased ligand expression in mesenchymal cells
and increased proliferation of the endothelium. Further-Figure 1. Venous Malformations
more, Vikkula et al. suggest that, by some as yet un-Top: Child with a venous malformation.
known mechanism, the TIE2 “receptor ligand loop” isBottom: Diagrams to show the histological difference between nor-
coupled to chemotaxis and proliferation of mesenchy-mal veins and a venous malformation. With increasing luminal diam-
eter, normal veins are lined by increasing numbers of endothelial mal cells as well as their differentiation into smooth
cells in a monolayer, and increasing numbers of smooth muscle muscle cells. Together these result in “uncoupling be-
cells inmultiple layers. In contrast, as the luminal diameter of venous tween proliferation and differentiation of endothelial
malformations increases, the number of smooth muscle layers does
cells and smooth muscle cells” and to a “disproportion-not increase.
ate number of endothelial and smooth muscle cells in
venous malformations.”
result in defects in recruitment of vascular wall cells. Incorporating two additional pieces of information
Angiopoietin-1 null mice have “a simplified and less provided by the Suri and Davis papers, we suggest a
complex vasculature containing fewer branches and modified interpretation. First, because angiopoietin-1
more homogeneously-sized vessels” and reveal little ev- has no mitogenic effect on endothelial cells, the putative
idence of endothelial proliferation. In fact, the authors endothelial proliferation that would be necessary for en-
show no change in the total number of endothelial cells dothelial cells to line a large lumen in the venous malfor-
between angiopoietin-null and normal embryos, based mation, may be a downstream event. Secondly, angio-
on Northern analysis of PE-CAM an endothelial marker. poietin-1 null embryos have reduced TIE2 receptor
In contrast, in the human venous malformation, the ab- mRNA, suggesting that the receptor levels are a function
normally large lumens suggest that there must have of the ligand and perhaps not the reverse as put forth
been endothelial proliferation. These differences could by Vikkula et al. (See Figure 2 diagram).
be real and reflect differences in the nature of the gene In our proposed model, angiopoietin-1 produced by
defects, e.g., null versus activating, or they could be mesenchymal cells activates the TIE2 receptor on endo-
due to the fact that one lesion (venous malformation) thelial cells, which in turn leads to the production and
forms in an adult organism whereas the other (angio- or release of a recruiting signal for mesenchymal cells.
poietin-1 deficiency) is occurring in a developing mouse In the case of the pericyte, most data indicate that this
embryo. We suspect that the increased endothelial pro- recruiting signal is PDGF-BB. But at the level of the
liferation in the venous malformations is secondary to smooth muscle, this recruitment also may involve
the absence of smooth muscle cells (see below). PDGF-AA or HB-EGF (heparin-binding epidermalgrowth
factor), another smooth muscle chemotactic factor andEven the assembly of a vascular structure seemingly
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have altered production of PDGF-BB or HB-EGF and/
or reduced ability to recruit smooth muscle cells or their
precursors? Do endothelial cells in venous malforma-
tions express normal levels of PDGF or HB-EGF?
What do these new data teach us about the develop-
ment of blood vessels? The TIE2/angiopoietin system
appears to govern maturation and stabilization of blood
vessels. ’Stabilization’ of a blood vessel is a stage when
remodeling has ceased, new branches are not devel-
oping, and luminal size is constant, save for physiologi-
cal vasodilation and vasoconstriction. Thus, the identifi-
cation and initial characterization of the TIE2 receptor
angiopoietin-1 system, begins to elucidate mechanisms
for a process which was formerly understood only at a
descriptive level. These three papers signify exciting
progress in vascular biology because they begin to re-
veal the molecular basis for vascular remodeling.
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